DSG1 and metabolic disease: In conclusion, our in vitro study suggests that DSG and 5-MOP may improve insulin resistance through an ERα-mediated PI3K/Akt activation pathway that implicates a novel therapeutic approach using this natural product in the treatment of metabolic diseases such as T2DM.